- Home
- AVB vs A Comparison
AVB vs A Comparison
Compare AVB & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVB
- A
- Stock Information
- Founded
- AVB 1978
- A 1999
- Country
- AVB United States
- A United States
- Employees
- AVB N/A
- A N/A
- Industry
- AVB Real Estate Investment Trusts
- A Biotechnology: Laboratory Analytical Instruments
- Sector
- AVB Real Estate
- A Industrials
- Exchange
- AVB Nasdaq
- A Nasdaq
- Market Cap
- AVB 26.5B
- A 29.3B
- IPO Year
- AVB 1994
- A 1999
- Fundamental
- Price
- AVB $193.74
- A $121.63
- Analyst Decision
- AVB Hold
- A Hold
- Analyst Count
- AVB 15
- A 9
- Target Price
- AVB $224.33
- A $134.33
- AVG Volume (30 Days)
- AVB 985.7K
- A 1.2M
- Earning Date
- AVB 07-30-2025
- A 08-27-2025
- Dividend Yield
- AVB 3.68%
- A 0.82%
- EPS Growth
- AVB 37.52
- A N/A
- EPS
- AVB 8.13
- A 4.06
- Revenue
- AVB $3,020,968,000.00
- A $6,628,000,000.00
- Revenue This Year
- AVB $3.46
- A $6.34
- Revenue Next Year
- AVB $5.15
- A $5.46
- P/E Ratio
- AVB $23.41
- A $29.91
- Revenue Growth
- AVB 5.87
- A 0.56
- 52 Week Low
- AVB $180.40
- A $96.43
- 52 Week High
- AVB $239.29
- A $153.84
- Technical
- Relative Strength Index (RSI)
- AVB 51.73
- A 58.66
- Support Level
- AVB $189.14
- A $117.03
- Resistance Level
- AVB $193.90
- A $120.59
- Average True Range (ATR)
- AVB 3.26
- A 2.14
- MACD
- AVB 1.00
- A 0.45
- Stochastic Oscillator
- AVB 89.09
- A 92.08
About AVB AvalonBay Communities Inc.
AvalonBay Communities owns a portfolio of 290 apartment communities with over 88,000 units and is developing 19 additional properties with over 6,500 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.
About A Agilent Technologies Inc.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.